Hospira Shareholders Approve Pfizer Deal
Hospira shareholders on Wednesday approved the $16 billion sale of the Chicago-area company to Pfizer, one of the world’s largest pharmaceutical companies.
Once the deal closes, Hospira shareholders will receive $90 a share in cash, a 39 percent premium to the closing price Feb. 4, the day before the transaction was announced.
At a special meeting of shareholders, 140.7 million votes were cast in favor of the deal, 326,868 votes against and there were 469,970 abstentions, according to a Hospira securities filing.
Hospira makes injectable drugs and infusion technologies. The company also is a leading player in the emerging market for lower-priced knockoffs of costly biotech drugs.
Pfizer has said it expects the deal to close in the second half of the year.
This article appeared in print in edition of Hamodia.
To Read The Full Story
Are you already a subscriber?
Click "Sign In" to log in!
Become a Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Become a Print + Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Renew Print + Web Subscription
Click “Renew Subscription” below to begin the process of renewing your subscription.
